Speaker: Melanie Leveridge
Melanie graduated from the University of Bristol, UK with first class honors in Biology, and joined GSK in 2005. She has since held roles of increasing responsibility in high throughput screening, compound profiling and assay development, predominantly in support of respiratory, neuroscience and immune-inflammation therapy areas. Melanie has particular expertise in the application of high throughput mass spectrometry techniques for screening and compound profiling.
In her current role as Director of Screening, Profiling and Mechanistic Biology, at the GSK Medicines Research Centre in Stevenage UK, Melanie leads a department of 50 scientists who partner with therapy area units to select the best targets for small molecule drug discovery approaches. Her team develop and prosecute assays and mechanistic biology studies to understand target:molecule interactions using a range of biochemical, biophysical, cellular and phenotypic assay approaches.
In this webinar Melanie Leveridge explains how recent developments within Matrix Assisted Laser Desorption/Ionization Time of Flight Mass Spectrometry (MALDI-TOF) have offered an alternative to the limitations of high throughput MS detection. This will include the development and validation of assays for both small molecule and peptide analytes using MALDI-TOF coupled to nanolitre liquid handling; the latest advancements in the technology; sample preparation process to further increase throughput, robustness and remove bottlenecks, and future opportunities of the platform.
Following this webinar, you will be able to:
- Describe the advantages mass spectrometry offers for screening enzyme targets
- Discuss new techniques available to reduce analysis time
- Design and validate assays for small molecule and peptide analytes using MALDI-TOF coupled to nanoliter liquid handling
- Recognize throughput bottlenecks and create the means to remove them
- Describe the future of MALDI-TOF and nanoliter liquid handling